Dominari (NASDAQ:DOMH – Get Free Report) and Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Dominari and Sonoma Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dominari | 1 | 0 | 0 | 0 | 1.00 |
| Sonoma Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Earnings & Valuation
This table compares Dominari and Sonoma Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dominari | $18.15 million | 2.99 | -$14.70 million | $5.57 | 0.60 |
| Sonoma Pharmaceuticals | $14.29 million | 0.35 | -$3.46 million | ($2.04) | -1.40 |
Sonoma Pharmaceuticals has lower revenue, but higher earnings than Dominari. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Dominari has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.
Profitability
This table compares Dominari and Sonoma Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dominari | 110.86% | -50.80% | -44.80% |
| Sonoma Pharmaceuticals | -19.04% | -42.56% | -11.97% |
Insider & Institutional Ownership
42.5% of Dominari shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 55.3% of Dominari shares are owned by insiders. Comparatively, 24.6% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Dominari beats Sonoma Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Dominari
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.
